• About Us
  • Overview
  • Strategy
  • Management >
    • Board of Directors
    • Senior Management
  • Scientific Advisory Board
  • Job Opportunities
• Clinical Trials
  • Overview
• Products
  • Advanced Pipeline >
    • TroVax^®
    • ProSavin^®
    • Hi-8 MEL^®
    • MetXia^®
    • RetinoStat^®
  • Early-stage Pipeline >
    • StarGen^®
    • MoNuDin^®
    • SMN-1G
    • Innurex^®
    • ReQuinate^®
    • ImmStat^®
    • EndoAngio-GT
    • Targeted Antibody
• Technology
  • Gene Delivery Technologies
  • Gene Discovery and Target Validation
  • Antibody Delivery
  • Hypoxia Response Element
• Collaborations
  • Corporate Partnerships
  • Technology Licence Agreements
  • Scientific Collaborations and Advisors
• Investors
  • Financing History
  • Accounts
  • Share Price
  • Presentation >
    • Interim Results August 2008
    • Annual General Meeting May 2008
    • Annual Results March 2007
  • Web Casts
  • Announcements
  • Shareholder Meetings
  • Contact
• News
  • Announcements
  • Events
  • Media Coverage
• Contact Us
  • UK >
    • Contacts
    • Directions
    • Map
  • USA >
    • Contacts
    • Directions
    • Map

Oxford BioMedica has several partnerships in place for its proprietary products and gene delivery technologies.

ARIUS RESEARCH Visit website
Oxford BioMedica has a research and development collaboration with ARIUS Research of Canada to search for targets and develop novel immunotherapy products to treat cancer.

MOLMED Visit website
The Company has an agreement with MolMed which allows use of Oxford BioMedica’s retroviral ex vivo gene delivery technology for pipeline development. Oxford BioMedica receives an upfront licence fee, annual maintenance payments, milestone payments and product royalties.

SANOFI-AVENTIS Visit website
Oxford BioMedica has signed an exclusive global licensing agreement with sanofi-aventis to develop and commercialise TroVax^® for the treatment of cancer. The deal is valued at up to €518 million if all development and registration targets are met for certain defined indications, in addition to tiered royalties on future sales. The companies will co-fund the ongoing Phase III TRIST study in renal cancer and sanofi-aventis will fund all future research, development, regulatory and commercialisation activities.

SIGMA-ALDRICH Visit website
A strategic alliance with Sigma-Aldrich identifies them as Oxford BioMedica’s exclusive global partner in the development and marketing of research products based on the LentiVector technology. Under the agreement Oxford BioMedica will receive an upfront payment, annual minimum payments and royalties on sales.

VIRxSYS Visit website
Oxford BioMedica has a licence agreement with VIRxSYS Corporation that provides VIRxSYS with rights to utilise Oxford BioMedica’s VSV-G viral envelope technology for gene delivery in the production process of its anti-HIV/AIDS product VRX496 which is currently in Phase II trials. Under the agreement, Oxford BioMedica receives an upfront licence fee and annual maintenance payments, and will receive payments on the achievement of clinical and regulatory milestones by VIRxSYS and product royalties.

WYETH Visit website
Oxford BioMedica has a collaborative product development deal with Wyeth potentially valued at US$24 million to develop an antibody-targeted immunotoxin directed against the proprietary tumour associated antigen 5T4, which is also the key component of TroVax, the Company’s therapeutic cancer vaccine.

Website by College Hill - Life Sciences